Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
This article reports preclinical development of TUS, an oral kinase inhibitor currently in clinical development for treatment of AML. The article covers the studies of TUS activities on cellular targets and the nonclinical studies that supported the advancement of TUS to a phase I/II trial of TUS/VEN in refractory AML and a phase I/II trial of TUS/VEN/5-azacytidine in newly diagnosed patients with AML (NCT03850574).
Authors
- Stephen B. Howell (ORCID: https://orcid.org/0000-0002-0877-8226)
- William G. Rice (ORCID: https://orcid.org/0000-0001-5705-9474)
- Seung Hyun Jung
- Himangshu Sonowal (ORCID: https://orcid.org/0000-0002-2977-7636)
- Rafael Bejar (ORCID: https://orcid.org/0000-0002-5603-4598)
- Ranjeet Sinha (ORCID: https://orcid.org/0000-0002-2120-9714)
- Joo‐Yun Byun (ORCID: https://orcid.org/0000-0002-7865-2493)
Institutions
- University of San Diego (US)
- University of California San Diego (US)
- Yuhan (South Korea) (KR)
- Hanmi Pharmaceutical (South Korea) (KR)
- Aptose Biosciences (United States) (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0258
- Citations
- 5
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 2.27